Mayo Clinic Study Continues to Refine Most Effective Methods to Predict Alzheimer's Disease
Posted on: Tuesday, 14 July 2009, 08:00 CDT
Alzheimer's disease is a degenerative disorder of the brain in which nerve cells die over time, resulting in a steady loss of memory and other thinking abilities. An estimated 5.3 million Americans are living with Alzheimer's disease, and it is the sixth-leading cause of death in the U.S. Mild cognitive impairment is a transitional state between normal aging and the earliest features of Alzheimer's disease.
"The goal of this research is to try to predict who is going to develop Alzheimer's disease in the future," says Ronald Petersen, M.D., Ph.D., a neurologist at Mayo Clinic and the lead author of this study. "Ideally, we'd like to identify individuals before any damage is done in the brain. The sooner we intervene on this process with medications or other therapies, the greater impact we can have on lessening the number of people who will ultimately develop Alzheimer's disease."
Dr. Petersen and his team studied 1,261 individuals aged 70-89 years who were cognitively normal or had only slight memory impairment at the onset of the study. The individuals were followed for up to 10 years. Scores on a memory test and the clinical criteria for mild cognitive impairment (including a memory test as well as other assessments of cognitive function) were studied as possible predictors for eventual development of Alzheimer's disease. The team found that the clinical criteria for mild cognitive impairment was better able to predict who was going to develop Alzheimer's disease in the future.
"As the baby boomers age into the period of risk for Alzheimer's disease, we're talking about a significant number of individuals who may become cognitively impaired in the very near future," says Dr. Petersen. "Consequently, we need information like this about the best methods of early prediction so that we can develop therapies to prevent or treat the condition and avoid being overwhelmed by the burden of these individuals on the health care system."
Other members of the Mayo Clinic research team included David Knopman, M.D.; Bradley Boeve, M.D.;
About Mayo Clinic
Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in
SOURCE Mayo Clinic
Source: PR Newswire
Related Articles
- Biomarkers Could Help Predict Risk Of Alzheimer's Disease In Patients With Mild Cognitive Impairment
- Age-Related Eye Disease Could Be Linked With Cognitive Impairment
- Avineuro Announced Advancing Potent Small Molecule for Treatment of Alzheimer's Disease to Clinical Development
- Applied NeuroSolutions Achieves Q2 2008 Alzheimer's Disease Serum Diagnostic Development Program Milestone
- EPIX Pharmaceuticals Reports Compelling Clinical Results for PRX-03140 in Alzheimer's Disease; Statistically Significant Improvement in Cognitive Function Achieved Within Two Weeks
- Exonhit Identifies a Panel of Genes to Diagnose, From Blood, Alzheimer's Disease
- Mayo Clinic Develops Medical Device That Reduces the Need for Invasive Surgical Biopsy Procedures
- Kurve Technology Achieves Clinical Success in Alzheimer's Disease Study
- ExonHit Therapeutics Accelerates Its Clinical Development Programme in Alzheimer's Disease
- Mayo Clinic in Jacksonville, Fla., Part of Study on Alzheimer's
User Comments (0)

RSS Feeds